At the time of writing, Plus Therapeutics Inc [PSTV] stock is trading at $1.20, down -3.23%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PSTV shares have gain 4.35% over the last week, with a monthly amount drifted -13.67%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Plus Therapeutics Inc [NASDAQ: PSTV] stock has seen the most recent analyst activity on January 25, 2021, when Ladenburg Thalmann initiated its Buy rating and assigned the stock a price target of $8. Previously, Maxim Group started tracking the stock with Buy rating on October 16, 2020, and set its price target to $6.
For the past year, the stock price of Plus Therapeutics Inc fluctuated between $0.93 and $2.67. Plus Therapeutics Inc [NASDAQ: PSTV] shares were valued at $1.20 at the most recent close of the market.
Analyzing the PSTV fundamentals
According to Plus Therapeutics Inc [NASDAQ:PSTV], the company’s sales were 5.72M for trailing twelve months, which represents an 17.42% jump. Gross Profit Margin for this corporation currently stands at 0.26% with Operating Profit Margin at -3.43%, Pretax Profit Margin comes in at -3.02%, and Net Profit Margin reading is -3.02%. To continue investigating profitability, this company’s Return on Assets is posted at -1.85, Equity is 2.71 and Total Capital is 2.85. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.65.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.1167 points at the first support level, and at 1.0333 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3167, and for the 2nd resistance point, it is at 1.4333.
Ratios To Look Out For
It is important to note that Plus Therapeutics Inc [NASDAQ:PSTV] has a current ratio of 0.44. As well, the Quick Ratio is 0.44, while the Cash Ratio is 0.1. Considering the valuation of this stock, the price to sales ratio is 1.24.
Transactions by insiders
Recent insider trading involved Hawkins Richard J, Director, that happened on Sep 13 ’24 when 4000.0 shares were purchased. Director, Hawkins Richard J completed a deal on Sep 12 ’24 to buy 6285.0 shares. Meanwhile, Director Petersen Greg bought 12500.0 shares on Sep 11 ’24.
